Published in BMC Genomics on November 24, 2010
Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol (2012) 3.81
Synthetic spike-in standards for RNA-seq experiments. Genome Res (2011) 3.58
Single mammalian cells compensate for differences in cellular volume and DNA copy number through independent global transcriptional mechanisms. Mol Cell (2015) 1.48
Variation in RNA-Seq transcriptome profiles of peripheral whole blood from healthy individuals with and without globin depletion. PLoS One (2014) 1.01
A quantitative reference transcriptome for Nematostella vectensis early embryonic development: a pipeline for de novo assembly in emerging model systems. Evodevo (2013) 0.94
Tracking the best reference genes for RT-qPCR data normalization in filamentous fungi. BMC Genomics (2015) 0.93
Quality assurance of RNA expression profiling in clinical laboratories. J Mol Diagn (2011) 0.87
Comparative transcriptomics and metabolomics in a rhesus macaque drug administration study. Front Cell Dev Biol (2014) 0.86
Direct GR Binding Sites Potentiate Clusters of TF Binding across the Human Genome. Cell (2016) 0.86
Multicenter evaluation of a standardized protocol for noninvasive gene expression profiling. Am J Transplant (2013) 0.84
Evaluation of the External RNA Controls Consortium (ERCC) reference material using a modified Latin square design. BMC Biotechnol (2016) 0.84
VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. Cell Mol Neurobiol (2014) 0.83
Maternal 3'UTRs: from egg to onset of zygotic transcription in Atlantic cod. BMC Genomics (2012) 0.79
Clinical implementation of RNA signatures for pharmacogenomic decision-making. Pharmgenomics Pers Med (2011) 0.75
An international comparability study on quantification of mRNA gene expression ratios: CCQM-P103.1. Biomol Detect Quantif (2016) 0.75
Evaluation of bias associated with high-multiplex, target-specific pre-amplification. Biomol Detect Quantif (2015) 0.75
Urinary Biomarkers for Chronic Kidney Disease with a Focus on Gene Transcript. Chin Med J (Engl) (2017) 0.75
Integrative analysis associates monocytes with insufficient erythropoiesis during acute Plasmodium cynomolgi malaria in rhesus macaques. Malar J (2017) 0.75
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Housekeeping genes as internal standards: use and limits. J Biotechnol (1999) 19.05
Multiple-laboratory comparison of microarray platforms. Nat Methods (2005) 11.74
Real-time RT-PCR normalisation; strategies and considerations. Genes Immun (2005) 10.93
Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol (2006) 8.87
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Real-time PCR for mRNA quantitation. Biotechniques (2005) 7.80
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech (2004) 5.97
Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol (2006) 5.14
The External RNA Controls Consortium: a progress report. Nat Methods (2005) 4.24
Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinformatics (2005) 3.93
Properties of the reverse transcription reaction in mRNA quantification. Clin Chem (2004) 3.49
Evaluation of external RNA controls for the assessment of microarray performance. Nat Biotechnol (2006) 2.59
Universal RNA reference materials for gene expression. Clin Chem (2004) 2.53
Performance evaluation of commercial short-oligonucleotide microarrays and the impact of noise in making cross-platform correlations. BMC Genomics (2004) 2.52
Relative quantification of mRNA: comparison of methods currently used for real-time PCR data analysis. BMC Mol Biol (2007) 2.31
Comparison of algorithms for the analysis of Affymetrix microarray data as evaluated by co-expression of genes in known operons. Nucleic Acids Res (2006) 2.24
Meta-analysis of microarray results: challenges, opportunities, and recommendations for standardization. Gene (2007) 2.16
Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist (2008) 2.10
Consolidated strategy for the analysis of microarray spike-in data. Nucleic Acids Res (2008) 2.04
Comparison of in vitro and in vivo reference genes for internal standardization of real-time PCR data. Biotechniques (2006) 1.91
Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential. Curr Opin Biotechnol (2007) 1.71
Proposed methods for testing and selecting the ERCC external RNA controls. BMC Genomics (2005) 1.70
The end of the microarray Tower of Babel: will universal standards lead the way? J Biomol Tech (2006) 1.11
The promise of toxicogenomics. Curr Opin Mol Ther (2002) 1.04
Detection limits of several commercial reverse transcriptase enzymes: impact on the low- and high-abundance transcript levels assessed by quantitative RT-PCR. BMC Mol Biol (2007) 1.03
Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools. BMC Genomics (2007) 1.01
The development of microarray standards. Anal Bioanal Chem (2005) 0.93
Array of hope: expression profiling identifies disease biomarkers and mechanism. Biochem Soc Trans (2009) 0.87
Gene expression profiling for molecular staging and prognosis prediction in colorectal cancer. Expert Rev Mol Diagn (2004) 0.85
The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments. Clin Chem (2013) 3.38
Evaluation of digital PCR for absolute DNA quantification. Anal Chem (2011) 2.34
Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res (2012) 1.97
Standardisation of data from real-time quantitative PCR methods - evaluation of outliers and comparison of calibration curves. BMC Biotechnol (2005) 1.25
Methods for applying accurate digital PCR analysis on low copy DNA samples. PLoS One (2013) 1.21
Applicability of RNA standards for evaluating RT-qPCR assays and platforms. BMC Genomics (2011) 1.14
Evaluation of digital PCR for absolute RNA quantification. PLoS One (2013) 1.13
Application of next generation qPCR and sequencing platforms to mRNA biomarker analysis. Methods (2012) 1.11
Microarray data quality - review of current developments. OMICS (2007) 1.09
Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem (2014) 1.08
The development of microarray standards. Anal Bioanal Chem (2005) 0.93
Comparison of reverse transcription-quantitative polymerase chain reaction methods and platforms for single cell gene expression analysis. Anal Biochem (2012) 0.92
A comparison of miRNA isolation and RT-qPCR technologies and their effects on quantification accuracy and repeatability. Biotechniques (2013) 0.91
Evaluation of a novel approach for the measurement of RNA quality. BMC Res Notes (2010) 0.84
Considerations for accurate gene expression measurement by reverse transcription quantitative PCR when analysing clinical samples. Anal Bioanal Chem (2014) 0.84
Validation of reference gene stability for APAP hepatotoxicity studies in different in vitro systems and identification of novel potential toxicity biomarkers. Toxicol In Vitro (2010) 0.83
Development of a facile fluorescent assay for the detection of 80 mutations within the p53 gene. Mol Med (2002) 0.82
Quality assessment of biobanked nucleic acid extracts for downstream molecular analysis. Biopreserv Biobank (2012) 0.80
An international comparability study on quantification of total methyl cytosine content. Anal Biochem (2008) 0.80
A pilot study to evaluate the application of a generic protein standard panel for quality control of biomarker detection technologies. BMC Res Notes (2011) 0.75
Improved detection of cell surface proteins using an electrochemiluminescent cell-binding assay. J Immunol Methods (2010) 0.75